Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Jeffrey B. Locke, PhD

Sr. Director Microbiology
Cidara Therapeutics

Disclosure(s): Cidara Therapeutics: Employee, Stocks/Bonds

Poster(s):

231 - Outcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia and/or Invasive Candidiasis
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
592 - Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET